Glucagon
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Fatty Liver Disease
Conditions
Non-Alcoholic Fatty Liver Disease, Glucagon Resistance
Trial Timeline
Feb 8, 2021 → Dec 9, 2021
NCT ID
NCT04859322About Glucagon
Glucagon is a pre-clinical stage product being developed by Novo Nordisk for Non-Alcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04859322. Target conditions include Non-Alcoholic Fatty Liver Disease, Glucagon Resistance.
What happened to similar drugs?
0 of 4 similar drugs in Non-Alcoholic Fatty Liver Disease were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04859322 | Pre-clinical | Completed |
Competing Products
20 competing products in Non-Alcoholic Fatty Liver Disease